Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males With Advanced and Platinum-resistant Germ-cell Tumors. An Open Label, Single Group, Phase 2 Trial
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 22 Feb 2018 New source identified and integrated (European Clinical Trials Database; EudraCT2012-004508-36).
- 06 Feb 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated